Acute myeloid leukemia (AML) drug, Rydapt, receives FDA approval
by Press Release from Outbreak News Today on (#2MSWN)
The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy. The drug is approved for use with a companion diagnostic, the LeukoStrat CDx FLT3 Mutation Assay, which is used to ["]
The post Acute myeloid leukemia (AML) drug, Rydapt, receives FDA approval appeared first on Outbreak News Today.